Answers are grounded in this paper and cite their sources.
Liver cancer is the third most common cancer-related death in the World. Hepatocellular carcinoma (HCC) constitutes %70-85 of liver malignant primary tumors. In this study; we aimed to investigate the role of diethylnitrosamine (DEN) in the experimental liver cancer model and to examine the hepatoprotective effect of silymarin in detail using oxidative-nitrosative stress markers with immunohistochemical methods. For this purpose, 50 Wistar Albino male rats were divided into 5 groups with 10 rats. Animals in DEN group received DEN at a dose of 50 mg/kg once a week for 20 weeks. The rats in the DEN +Silymarin group were Silymarin intraperitoneally for 21 weeks 3 times a week at a dose of 100 mg/kg, starting 1 week prior to the administration of DEN. Silymarin was administered to rats in the group of Silymarin 3 times a week intraperitoneally for 20 weeks at a dose of 100 mg/kg. The rats in the control group were fed pellet feed and drinking water for 20 weeks. Animals in Sham group were treated with propylene glycol dissolved in 0,9 % NaCl intraperitoneally 3 times a week for 20 weeks. At the end of 21 weeks, macroscopically different size and number of nodular structures were detected in the DEN and DEN+Silymarin group. The microscopic examination revealed that the nodules were HCC. As a result, DEN induced liver cancer; however, silymarin did not show a statistically significant protective effect in terms of iNOS and Nitrotyrosine expressions.
No takes yet. Share an insight, caveat, or question.
KARAKURT et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: